Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Investing

Acceleration of RAD204 Phase 1 dose escalation trial

by admin May 12, 2025
May 12, 2025
Acceleration of RAD204 Phase 1 dose escalation trial

Radiopharm Theranostics (RAD:AU) has announced Acceleration of RAD204 Phase 1 dose escalation trial

Download the PDF here.

This post appeared first on investingnews.com

previous post
Multiple New Multi-Commodity Targets
next post
Excellent Gold Intersections Verified at Kiimala Project

Related Posts

SAGA Metals Commences Drilling at Radar Ti-V Project...

February 20, 2025

Alice Queen raises $1M via issue of Convertible...

September 16, 2025

Silver Crown Confirms Receipt of Royalty Payments and...

March 21, 2025

Rio Tinto and Calix to Partner on Zero...

November 18, 2025

Oversubscribed Share Purchase Plan Raises $1.5 Million

November 27, 2025

Guide to Uranium Mining in Canada

August 21, 2025

Prismo Metals Closes Acquisition of Increased Interest in...

January 16, 2026

Significant Gold and Antimony Grades Confirmed at Hurricane...

February 17, 2025

Syntholene Energy Corp Strengthens Advisory Board with Former...

February 5, 2026

Steve Barton: Silver, Gold at New Highs, Here’s...

January 23, 2026

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 4

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • Terms and Conditions
    • Privacy Policy

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 wallstreetwizardry.com | All Rights Reserved